Revance Therapeutics, Inc. (RVNC) disclosed on Monday that it has entered into a merger agreement with Crown Laboratories, Inc., which plans to purchase all outstanding shares of Revance's common stock for $6.66 per share in cash. This transaction signifies a total enterprise value of $924 million and represents an 89% premium relative to Revance's closing price on August 9, 2024. Following the news, the stock rose 85% in pre-market.
The objective of the merger is to establish a prominent and innovative company in the aesthetics and skincare sector, integrating Crown's skincare products with Revance's aesthetic solutions.
Upon the successful completion of the merger, Revance will become a wholly owned subsidiary of Crown, and its stock will cease to be publicly traded on Nasdaq.
The transaction is anticipated to be finalized by the end of the year, pending stockholder approval and necessary regulatory clearances.
In pre-market activity on the Nasdaq, the shares are trading at $6.58, up 85.40%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.